TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02479685

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PKS BILL-PKS PlasmaSORD Versus Conventional surgical techniques
Description: To verify if the operative time of a standard laparoscopic sacral colpopexy associated to subtotal hysterectomy for the treatment of POP could be further reduced using PKS BILL: bipolar laparoscopic loop (a laparoscopic loop using advanced bipolar energy) (Olympus Medical Systems Corp, Tokyo) and PKS PlasmaSORD (Solid Organ Removal Device) vs. conventional monopolar hook and conventional mechanic morcellator.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PKS BILL-PKS PlasmaSORD Versus Conventional surgical techniques
Description: To verify if the operative time of a standard laparoscopic sacral colpopexy associated to subtotal hysterectomy for the treatment of POP could be further reduced using PKS BILL: bipolar laparoscopic loop (a laparoscopic loop using advanced bipolar energy) (Olympus Medical Systems Corp, Tokyo) and PKS PlasmaSORD (Solid Organ Removal Device) vs. conventional monopolar hook and conventional mechanic morcellator.
Study: NCT00962533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telbivudine
Description: telbivudine, 600mg, oral, daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: telbivudine
Description: telbivudine, 600mg, oral, daily
Study: NCT04011566

Intervention type: DIAGNOSTIC_TEST
Intervention: ShuntCheck
Description: The intervention is an FDA-cleared device utilizing a transcutaneous thermal convection to analyze shunt flow.
Study: NCT03490591

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robot-assisted hand rehabilitation
Description: Robot-assisted hand rehabilitation: 20 minute of warm-up exercise and 40 minute of robot-assisted hand exercise intervention. Robot-assisted hand exercises include passive range of motion of hand, bilateral hands task, robot-assisted task, and game task.
Study: NCT00680355

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: golden rice
Description: An acute dose of cooked golden rice containing \~ 1 mg of ß-carotene

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: golden rice
Description: An acute dose of cooked golden rice containing \~ 1 mg of ß-carotene

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: golden rice
Description: An acute dose of cooked golden rice containing \~ 1 mg of ß-carotene

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: corn oil 0g
Description: 0 g of corn oil in the golden rice meal

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: corn oil 10g
Description: 10g corn oil in the golden rice meal

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: coren oil 5 g
Description: golden rice meal with 5 g corn oil
Study: NCT01772524

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD403

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04187144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: Gepotidacin will be available as tablets at a unit dose strength of 750mg. Participants will administer two 750 mg tablets, BID. Each dose will be taken with water after consumption of food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching nitrofurantoin
Description: Placebo matching nitrofurantoin will be available as over-encapsulated unit-dose capsules. Participants will administer 1 capsule BID. Each dose should be taken with water after consumption of food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin
Description: Nitrofurantoin will be available as over-encapsulated 100 mg capsules containing 25 mg nitrofurantoin macrocrystals and 75 mg nitrofurantoin. Participants will administer one 100 mg capsule, BID. Each dose should be taken with water after consumption of food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching gepotidacin
Description: Placebo matching gepotidacin will be available as unit-dose gepotidacin placebo-to-match tablet. Participants will administer two tablets, BID. Each dose should be taken with water after consumption of food.
Study: NCT00464373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Single intrasphincteric injection at the 3,6,9, and 12 o'clock positions of the external urethral sphincter (1 ml of drug solution each)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4ml NaCl 0.9%
Study: NCT00808613

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optetrak PS
Description: Optetrak Posterior Stabilized total knee replacement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optetrak Hi-Flex
Description: Optetrak Hi-Flex total knee replacement
Study: NCT00996515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-azacytidine, erlotinib
Description: Erlotinib 150 mg PO daily, days 1-8, and 15-22 5-Azacytidine 75 mg/m2/day, IV days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-azacytidine, erlotinib
Description: Erlotinib 150 mg PO daily, days 1-8, and 15-22 5-Azacytidine 75 mg/m2/day, IV days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-azacytidine, erlotinib
Description: Erlotinib 150 mg PO daily, days 1-8, and 15-22 5-Azacytidine 75 mg/m2/day, IV days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-azacytidine, erlotinib
Description: Erlotinib 150 mg PO daily, days 1-8, and 15-22 5-Azacytidine 75 mg/m2/day, IV days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-azacytidine, erlotinib
Description: Erlotinib 150 mg PO daily, days 1-8, and 15-22 5-Azacytidine 75 mg/m2/day, IV days 1 and 15
Study: NCT00996515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib PO and Vidaza IV
Description: Patients enrolled to 1 of 5 cohorts, with varying drug doses and dose scheduling.
Study: NCT02663804

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty
Study: NCT01214759

Intervention type: DRUG
Group type: OTHER
Intervention: Truvada
Description: Tenofovir 200mg/emtricitabine 300mg once a day

Intervention type: DRUG
Group type: OTHER
Intervention: Raltegravir
Description: Raltegravir 400mg twice a day
Study: NCT00996515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib PO and Vidaza IV
Description: Patients enrolled to 1 of 5 cohorts, with varying drug doses and dose scheduling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib PO and Vidaza IV
Description: Patients enrolled to 1 of 5 cohorts, with varying drug doses and dose scheduling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib PO and Vidaza IV
Description: Patients enrolled to 1 of 5 cohorts, with varying drug doses and dose scheduling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib PO and Vidaza IV
Description: Patients enrolled to 1 of 5 cohorts, with varying drug doses and dose scheduling.
Study: NCT03055728

Intervention type: DIAGNOSTIC_TEST
Intervention: Rapid strep antigen detection test
Description: Pharyngeal swab for rapid antigen detection of streptococcus

Intervention type: DIAGNOSTIC_TEST
Intervention: Rapid strep antigen detection test
Description: Pharyngeal swab for rapid antigen detection of streptococcus

Intervention type: DIAGNOSTIC_TEST
Intervention: throat culture
Description: Pharyngeal swab for culture for bacteria (specifically streptococcus) presence

Intervention type: DIAGNOSTIC_TEST
Intervention: throat culture
Description: Pharyngeal swab for culture for bacteria (specifically streptococcus) presence
Study: NCT02330666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mission Possible: Parents & Kids Who Listen
Description: MP is a 12-hour, 6-session, manualized skills training program with 2 boosters. Behavioral strategies teach adults and youth to communicate with one another emphasizing youth's need for flexible family boundaries, emotional closeness, and adults as resources. Dyads attend together. Sessions begin with relaxation exercises, review of the prior week's lessons and homework, and examination of success and failure in trying communication techniques. New concepts are introduced using didactic videotaped presentations. Lively, interactive, developmentally appropriate group exercises follow reflective of ethnic diversity that are reinforced with handouts and encouragement to try them at home. Week-by-week content covers: Developmental Changes; Self-Esteem; Communicating What You Want; Listening to What the Other Wants; Solving Conflicts; and Letting Go. The booster sessions are 2 hours in length and update developmental concepts; 5 basic listening skills; and 6 conflict resolution steps.
Study: NCT01892436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17).
Study: NCT00042965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study: NCT03998098

Intervention type: DIAGNOSTIC_TEST
Intervention: Oxygen Saturation (Oximetry)
Description: Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers

Intervention type: DIAGNOSTIC_TEST
Intervention: Heart Rate (Pulse)
Description: Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers
Study: NCT02468323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients will receive regular spinal anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Patients will receive slow intravenous injection of ondansetron 4 mg after cord clamping

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron
Description: Patients will receive slow intravenous injection of ondansetron 4 mg after cord clamping
Study: NCT03998098

Intervention type: DIAGNOSTIC_TEST
Intervention: Respiratory Rate
Description: Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Pressure
Description: Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers For participants only participating in the Blood Pressure Arm of the trial, they will not be required to enter the normobaric chamber but will have their blood pressure readings taken in the ambient environment including lying supine in order to generate hypotensive readings.
Study: NCT00739934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voriconazole (Vfend)
Description: Study Days 1 to 7: IV voriconazole 7 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 200 mg q12h~Notes:~1. If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.~2. Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.~(IV = Intravenous; POS = Powder for oral suspension)
Study: NCT02745990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Description: rhEPO is administered 500IU/kg, intravenously within 72h after birth, and every other day up to 32 weeks of corrected age.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal salin is administered the same volume with rhEPO intravenously within 72h after birth, and every other day up to 32 weeks of corrected age..
Study: NCT03577106

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Description: Theta Burst Stimulation (TBS), a form of TMS, will be targeted to the Inferior Parietal Cortex based on neural navigation software. TBS will be delivered for about 5-6 minutes, five days a week for two weeks, for a total of ten sessions.
Study: NCT01235520

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral doses, once a day for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: Oral dose level 1, once a day for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: Oral dose level 2, once a day for 52 weeks
Study: NCT01892436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT04020913

Intervention type: DRUG
Intervention: Somatropin injection
Description: Boys with short stature will be studied for measures of:~1. skeletal muscle strength, power, and endurance~2. muscle agility~3. lean body mass accrual~4. bone mineral density and resting energy expenditure before and after 6 months and 12 months of GH administration
Study: NCT04527003

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol (CBD) Extract
Description: Cannabis is a well-known plant that contains more than 500 identified phytochemicals of which over 100 are cannabinoids. The most widely studied is 9-tetrahydrocannabinol (9-THC), which is the major psychoactive component of Cannabis, but Cannabidiol (CBD) has been increasingly favored for its reduced side effect profile and potential health benefits. CBD was first isolated from Cannabis in the 1940s. CBD, unlike 9-THC, does not bind to CB1 and CB2 receptors, which accounts for its lack of typical psychotropic effects, but is still appears to work via alternative mechanisms via the endocannabinoid system.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol (CBD) Extract
Description: Cannabis is a well-known plant that contains more than 500 identified phytochemicals of which over 100 are cannabinoids. The most widely studied is 9-tetrahydrocannabinol (9-THC), which is the major psychoactive component of Cannabis, but Cannabidiol (CBD) has been increasingly favored for its reduced side effect profile and potential health benefits. CBD was first isolated from Cannabis in the 1940s. CBD, unlike 9-THC, does not bind to CB1 and CB2 receptors, which accounts for its lack of typical psychotropic effects, but is still appears to work via alternative mechanisms via the endocannabinoid system.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Norethindrone Acetate
Description: Norethindrone is a form of progesterone, a female hormone important for regulating ovulation and menstruation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norethindrone Acetate
Description: Norethindrone is a form of progesterone, a female hormone important for regulating ovulation and menstruation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norethindrone Acetate
Description: Norethindrone is a form of progesterone, a female hormone important for regulating ovulation and menstruation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a substance or treatment which is designed to have no therapeutic value
Study: NCT03523572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: The investigational product is a sterile lyophilized powder, which is made into solution for intravenous administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: The investigational product is a sterile lyophilized powder, which is made into solution for intravenous administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: The investigational product is a sterile lyophilized powder, which is made into solution for intravenous administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: The investigational product is a sterile lyophilized powder, which is made into solution for intravenous administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: The investigational product is a sterile lyophilized powder, which is made into solution for intravenous administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: The investigational product is a sterile lyophilized powder, which is made into solution for intravenous administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is an aqueous solution formulated at 10 mg/mL to be administered at a flat dose of 360 mg IV over 30 minutes. Protocol-defined thyroid testing is required while taking nivolumab.
Study: NCT01892436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT01851265

Intervention type: DRUG
Group type: OTHER
Intervention: Olaparib
Description: 400mg olaparib capsule formulation taken 30 minutes after allocated meal. 5-14 days between arms.

Intervention type: DRUG
Group type: OTHER
Intervention: Olaparib
Description: 400mg olaparib capsule formulation taken 30 minutes after allocated meal. 5-14 days between arms.

Intervention type: DRUG
Group type: OTHER
Intervention: Olaparib
Description: 400mg olaparib capsule formulation taken 30 minutes after allocated meal. 5-14 days between arms.

Intervention type: OTHER
Group type: OTHER
Intervention: Dietary Fasted
Description: Allocated breakfast prior to dosing with 400mg olaparib capsules

Intervention type: OTHER
Group type: OTHER
Intervention: Dietary standard
Description: Allocated breakfast prior to dosing with 400mg olaparib capsules

Intervention type: OTHER
Group type: OTHER
Intervention: Dietary High Fat
Description: Allocated breakfast prior to dosing with 400mg olaparib capsules
Study: NCT04089241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contrast 3D Ultrasound
Description: an ultrasound examination which will include a 3D reconstruction and thereafter CEUS will be performed using SONOVIEW contrast agent
Study: NCT02403817

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: A collection of video games that rely on various aspects of visual behavior (i.e. sustained attention, vigilance, rapid discrimination, etc) for successful play.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: A collection of video games that rely on various aspects of visual behavior (i.e. sustained attention, vigilance, rapid discrimination, etc) for successful play.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye Motor Training
Description: Game play will be controlled by the player's eye movements (via an eye tracking device)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hand Motor Training
Description: Game play will be controlled by the player's hand movements (via a joystick).
Study: NCT00886886

Intervention type: DRUG
Group type: OTHER
Intervention: MDMA
Description: 125 mg, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Reboxetine, 8 mg
Description: two doses 12h and 2h before MDMA

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: capsules identical to MDMA or Reboxetine
Study: NCT01461265

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cryoablation
Description: For cryoablation in the palliation of painful bone metastases, subject preparation, anesthesia, intra-operative monitoring, and postoperative management are identical to those of standard cryoablation routinely performed at all clinical centers participating in this study and are at the discretion of the investigator.
Study: NCT02468323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Patients will receive slow intravenous infection of palonosetron 75 mcg after cord clamping

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Palonosetron
Description: Patients will receive slow intravenous infection of palonosetron 75 mcg after cord clamping